Physician profile
Yanting Wang
NPI 1073964656
$3,668.36
in general payments reported to CMS, 2019-2025
16 companies · $2,923 in 2025
The $2,923 reported for 2025 was more than what 88% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $186 · 2023: $497 · 2024: $61.56 · 2025: $2,923.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,695 · Food and Beverage: $787.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,695.00 |
| Food and Beverage | $787.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $2,845.07 | 2022-2025 | Camzyos, Cobenfy, Eliquis |
| Astrazeneca Pharmaceuticals Lp | $276.58 | 2022-2025 | Lokelma, Farxiga |
| Corcept Therapeutics | $103.80 | 2025 | Korlym |
| Boehringer Ingelheim Pharmaceuticals, INC. | $88.02 | 2022-2023 | Jardiance |
| Pfizer INC. | $74.68 | 2022-2023 | |
| Abbott Laboratories | $51.20 | 2022 | |
| Amgen INC. | $44.62 | 2022-2024 | Repatha |
| Angiodynamics, INC. | $31.00 | 2025 | Angiovac |
| Novartis Pharmaceuticals Corporation | $29.36 | 2023 | |
| Amarin Pharma, INC. | $27.18 | 2023 | |
| Philips North America LLC | $21.15 | 2023 | |
| Esperion Therapeutics, INC. | $16.80 | 2023 | Nexletol |
| Sanofi-Aventis U.S. LLC | $16.59 | 2023 | |
| Novo Nordisk INC | $15.63 | 2023 | Ozempic |
| Irhythm Technologies, INC. | $14.94 | 2024 | Zio Monitor, Zio Xt Patch |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| W. L. Gore & Associates, INC. | $11.74 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yanting Wang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.